Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Comment by lscfaon Jan 06, 2021 4:27pm
156 Views
Post# 32235602

RE:RE:RE:RE:New info out

RE:RE:RE:RE:New info out

Also, I think the R+F contract is delayed due to 0.4% trials. I no longer believe mgmt BS in Dec 2019 NR.  Recall Obagi cancelled its contract when Sirona went and produced a better version of the skin ligthener.   


Dec 2, 2019 - "The planned clinical trial is anticipated to be a value-add for the compound. Current licenses and ongoing product development by partners for TFC-1067 will not be delayed by the studies."



lscfa wrote: Can't trust mgmt. When the 0.2% results came out mgmt did not mention that 1067 failed to lighten skin other than dark spots. Shareholders found out about this much later when the study was finally published for all to see.   
 

wexworth wrote:
it says the 0.4% trial is nearing completion. Am I missing something here because you can take any biotech on the planet, and when they release positive clinical results (to be determined in this case), their share prices go up, and depending upon the nature of the results, goes way up. You are certainly welcome to your widget factory comparison.




<< Previous
Bullboard Posts
Next >>